Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Bobak Azamian

Tarsus Pharmaceuticals, Inc.

Ophthalmic Consultants of Boston provides eye care services, including cataract surgery, LASIK, and retinal care. The practice is self-described as a multi-specialty ophthalmology practice with a history of innovation since 1969.

Ophthalmic Consultants of Boston

Grin Eye Care provides comprehensive eye care services, including cataract surgery, laser vision correction, and products like glasses and contacts. The company is self-described as dedicated to meeting all ophthalmology needs.

Grin Eye Care

SIEHT is a healthcare provider specializing in eye care services, including cataract surgery, LASIK vision correction, glaucoma treatment, and general eye exams.

SIEHT

Tarsus (NASDAQ:TARS) is a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care.

Armentum Partners

Horowitz Group

Vivo Capital

Aperture Venture Partners

Visionary Venture Fund

Flying L Partners

Frazier Healthcare Partners

The first and only FDA-approved treatment for Demodex blepharitis (DB) is now available! We’re delighted to introduce this new therapeutic to the eye care community and thrilled at its potential to help many patients living with this disease.

We are so appreciative of our superstar Tarsus team and the many partners who worked diligently to make this important milestone happen. 

Read the full press release here: https://lnkd.in/eEQW3SEv

🌺 Aloha from the Hawaiian Eye & Retina 2024 Meeting! 

We love kicking off the New Year by attending this important and engaging meeting! This year, we had the privilege of connecting with leading experts in eye care across a variety of different platforms to share experiences about Demodex blepharitis and eyelid health. We appreciate the unique perspectives and compelling discussion and look forward to continuing the dialogue as we move further into 2024. 

Today, we commemorate the incredible life and impact of Dr. Martin Luther King Jr.

His unwavering dedication to justice, equality, and unity continues to inspire us. Dr. King had a vision for a brighter, more inclusive future, and we strive to honor that vision in everything we do at Tarsus.

This #MLKDay, we encourage our Tarsans to volunteer in their communities and reflect on Dr. King's commitments to peace, service, and education.

The Tarsus crew celebrated the holidays and rang in the New Year traveling, relaxing and spending time with loved ones!

We prioritize the health and well-being of our Tarsans and look forward to this important recharge break at the end of each year. Swipe through to see some highlights of our winter wellness week.

Discover more about the values that shape our culture: https://lnkd.in/eGeFU8_E

As we bid farewell to 2023, we’d like to reflect on what an incredible year it’s been.

2023 was a milestone year – we received FDA approval for the first and only treatment for Demodex blepharitis and just a few weeks into launch, we are well on our way to helping millions of potential patients. We experienced tremendous growth as an organization, more than doubling in size, and we were recognized by numerous independent companies as a great place to work.

We are grateful to our investigators, eye care provider partners, patients and our passionate team of Tarsans who helped us get to where we are today.

We are inspired and motivated to start 2024 and continue to deliver on our vision to make a meaningful difference in eye care and to the patients we serve. We wish everyone a happy and healthy holiday season.

See here for XDEMVY prescribing info: https://bit.ly/3Rrf4YB

Metric
Company Name	Tarsus Pharmaceuticals, Inc.	Ophthalmic Consultants of Boston	Grin Eye Care	SIEHT
Symbol	TARS
MSH ID	COM:TARSUSRX	COM:EYEBOSTON	COM:GRINEYECARE	COM:SIEHT
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Ophthalmology	Healthcare	Optometry
Country	US	US	US	US
Stage
Employee Count	244		11
Website	tarsusrx.com	eyeboston.com	grineyecare.com	sieht.com
LinkedIn	tarsus-pharmaceuticals-inc
Founders

Metric
Market Cap	1.07B
Enterprise Value
Monthly Web Traffic		3.26K	419
Web Traffic Growth		10.82	-0.85
Valuation
Raised Capital

Metric
Revenue	17.45M
Revenue (LTM)
Revenue (NTM)
Gross Profit	15.85M
EBITDA	-142.28M
Operating Income	-143.16M
Net Income	-135.89M
EPS	-4.62
Diluted EPS	-4.62
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.94
Operating Profit Margin	-1.88
EBITDA Margin	-8.16
Net Profit Margin	-1.80
Return on Equity	-0.64
Return on Assets	-0.40
Return on Capital Employed	-0.48

COM:TARSUSRX

Tarsus Pharmaceuticals, Inc.

Last Close

46.40

22/11 21:00

Market Cap

1.07B

Beta: -

Volume Today

589.21K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.21
P/B Ratio	4.06
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	43.90
EV Multiple	-6.37

Metric
Days Sales Outstanding	78.42
Days Payables Outstanding	4.88K
Days Inventory Outstanding	524.05
Operating Cycle	721.64
Cash Conversion Cycle	611.37
Asset Turnover	0.22

Metric
Operating Cash Flow	-117.49M
Free Cash Flow	-123.00M
Cash Flow to Debt
Operating Cash Flow/Sales	-1.49
Free Cash Flow Yield	-0.10

Metric
Cash & Equivalents	224.95M
Accounts Receivable	-14.13M
Inventory	3.11M
Goodwill
Debt to Capitalization	0.22
Debt to Assets	0.11
Current Ratio	11.15
Quick Ratio	7.92

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.61
R&D to Revenue	1.59
SG&A to Revenue	2.71